Advertisement

Journal of Neuro-Oncology

, Volume 141, Issue 1, pp 103–109 | Cite as

Large volume re-irradiation for recurrent meningioma with pulsed reduced dose rate radiotherapy

  • Jacob S. Witt
  • Hima B. Musunuru
  • R. Adam Bayliss
  • Steven P. HowardEmail author
Clinical Study

Abstract

Purpose

Meningiomas comprise up to 30% of primary brain tumors. The majority of meningioma patients enjoy high rates of control after conventional therapies. However, patients with recurrent disease previously treated with radiotherapy have few options for salvage treatment, and systemic interventions have proven largely ineffective. The aim of this study was to determine whether pulsed reduced dose rate radiotherapy (PRDR) was well tolerated in a small cohort of patients with recurrent meningioma.

Methods

We retrospectively identified eight patients with recurrent intracranial meningioma treated with PRDR from April 2013 to August of 2017 at a single institution. All patients had radiographic and/or pathologic evidence of progression prior to treatment and had previously completed conventional radiotherapy. Acute and late toxicities were graded based on CTCAE 4.0.

Results

Of eight patients, six had histologically confirmed atypical meningiomas upon recurrence. All patients were re-treated with IMRT at an apparent dose rate of 0.0667 Gy/min. Median time between radiation courses was 7.7 years. Median PRDR dose was 54 Gy in 27 fractions to a median volume of 261.6 cm3. Two patients (25%) had in field failure with a median follow up of 23.3 months. PFS at 6 months was 100%. All but one (87.5%) patient was still alive at last follow up. No patient experienced grade ≥ 2 acute or late toxicities.

Conclusions

PRDR re-irradiation was well tolerated and appeared effective for a small cohort of patients with recurrent meningioma previously treated with radiotherapy. A phase II trial to assess this prospectively is in development.

Keywords

Meningioma Re-irradiation Radiation therapy CNS toxicity 

Notes

Acknowledgements

We thank Edward Bender, Ph.D., DABR. for his contribution to this work.

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Wiemels J, Wrensch M, Claus EB (2010) Epidemiology and etiology of meningioma. J Neurooncol 99(3):307–314CrossRefGoogle Scholar
  2. 2.
    Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM (1997) Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol 21(12):1455–1465CrossRefGoogle Scholar
  3. 3.
    Lagman C, Bhatt NS, Lee SJ et al (2017) Adjuvant radiosurgery versus serial surveillance following subtotal resection of atypical meningioma: a systematic analysis. World Neurosurg 98:339–346CrossRefGoogle Scholar
  4. 4.
    Goldsmith BJ, Wara WM, Wilson CB, Larson DA (1994) Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg 80(2):195–201CrossRefGoogle Scholar
  5. 5.
    Miralbell R, Linggood RM, De la Monte S, Convery K, Munzenrider K, Mirimanoff JE (1992) The role of radiotherapy in the treatment of subtotally resected benign meningiomas. J Neurooncol 13(2):157–164CrossRefGoogle Scholar
  6. 6.
    Rogers L, Zhang P, Vogelbaum MA et al (2017). Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg. 129:1–13Google Scholar
  7. 7.
    Feng R, Che X, Hu J, Pan L, Cui D, Yang L (2013) Surgical treatment of recurrent torcular meningiomas: case report and review of the literature. J Neurol Surg A Cent Eur Neurosurg 74(Suppl 1):e266–e270Google Scholar
  8. 8.
    Kaley T, Barani I, Chamberlain M et al (2014) Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro-oncology 16(6):829–840CrossRefGoogle Scholar
  9. 9.
    Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas. NCT02523014. https://clinicaltrials.gov/ct2/show/NCT02523014
  10. 10.
    Brastianos PK, Horowitz PM, Santagata S et al (2013) Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nature genetics 45:285CrossRefGoogle Scholar
  11. 11.
    Clark VE, Erson-Omay EZ, Serin A et al (2013) Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 24:1233009Google Scholar
  12. 12.
    Adkison JB, Tomé W, Seo S et al (2011) Reirradiation of large-volume recurrent glioma with pulsed reduced-dose-rate radiotherapy. Int J Radiat Oncol Biol Phys 79(3):835–841CrossRefGoogle Scholar
  13. 13.
    Richards GM, Tome WA, Robins HI et al (2009) Pulsed reduced dose-rate radiotherapy: a novel locoregional retreatment strategy for breast cancer recurrence in the previously irradiatedchest wall, axilla, or supraclavicular region. Breast Cancer Res Treat 114:307–313CrossRefGoogle Scholar
  14. 14.
    Joiner MC, Marples B, Lambin P et al (2001) Low-dose hypersensitivity: current status and possible mechanisms. Int J Radiat Oncol Biol Phys 49:379–389CrossRefGoogle Scholar
  15. 15.
    Harney J, Short SC, Shah N et al (2004) Low dose hyper-radiosensitivity in metastatic tumors. Int J Radiat Oncol Biol Phys 59:1190–1195CrossRefGoogle Scholar
  16. 16.
    Wojcieszynski AP, Ohri N, Andrews DW, Evans JJ, Dicker AP, Werner-wasik M (2012) Reirradiation of recurrent meningioma. J Clin Neurosci 19(9):1261–1264CrossRefGoogle Scholar
  17. 17.
    Hall EJ, Giaccia AJ (2018) Radiobiology for the radiologist, vol 7. Kluwer, South HollandGoogle Scholar
  18. 18.
    Marples et al (2008) Low-dose hyper-radiosensitivity: past, present, and future. Int J Radiation Oncology Biol Phys 70(5):1310–1318CrossRefGoogle Scholar
  19. 19.
    Tomè WA, Howard SP (2007) On the possible increase in local tumour control probability for gliomas exhibiting low dose hyperradiosensitivity using a pulsed schedule. Br J. Radiol 80:32–37CrossRefGoogle Scholar
  20. 20.
    Cannon GM et al (2007) Pulsed reduced dose-rate radiotherapy: case report, a novel re-treatment strategy in the management of recurrent glioblastoma multiforme. J Neurol Oncol 83:307–311CrossRefGoogle Scholar
  21. 21.
    Ma C et al (2012) Investigation of pulsed low dose rate radiotherapy using dynamic arc delivery techniques. Phys Med Biol 57:4613–4626CrossRefGoogle Scholar
  22. 22.
    Basch E, Reeve BB, Mitchell SA et al. (2014) Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 106(9):dju244CrossRefGoogle Scholar
  23. 23.
    Lee CT, Dong Y, Li T et al (2018) Local control and toxicity of external beam reirradiation with pulsed low-dose-rate technique. Int J Radiat Oncol Biol Phys.  https://doi.org/10.1016/j.ijrobp.2017.12.012 Google Scholar
  24. 24.
    Ji Y, Rankin C, Grunberg S et al (2015) Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol 33(34):4093–4098CrossRefGoogle Scholar
  25. 25.
    Combs SE, Welzel T, Habermehl D et al (2013) Prospective evaluation of early treatment outcome in patients with meningiomas treated with particle therapy based on target volume definition with MRI and 68 Ga-DOTATOC-PET. Acta Oncol 52(3):514–520CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Human OncologyUniversity of Wisconsin School of Medicine and Public HealthMadisonUSA
  2. 2.Department of Medical PhysicsUniversity of Wisconsin School of Medicine and Public HealthMadisonUSA

Personalised recommendations